Kolexia
Perre Philippe
Médecine interne
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, France
59 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Infections à VIH Hépatite C Hépatite Co-infection Cirrhose du foie Fibrose Hépatite C chronique Effets secondaires indésirables des médicaments Maladies du foie

Industries

A+A
28 collaboration(s)
Dernière en 2023
B3TSI
18 collaboration(s)
Dernière en 2023
P\S\L Group Services
18 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2023

Dernières activités

Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication.
Open forum infectious diseases   01 juillet 2021
CO19 COVERTE: Long Term Evaluation of Young Adults Born to HIV-infected Mothers. A Cohort of Young Adults Infected With HIV Since Birth or During Childhood
Essai Clinique (Agence nationale de recherches sur le sida et les hépatites virales)   04 décembre 2020
Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.
AIDS (London, England)   15 septembre 2020
Torque Teno Virus Viral Load could Predict Immunosuppression Level After Liver Transplantation
Abstracts of the 19\u003csup\u003eth\u003c/sup\u003e Annual Congress of the French Speaking Transplantation Society, Bordeaux, France, 4–6 December 2019   16 décembre 2019
Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis
Abstracts of the 17th European AIDS Conference, Basel, Switzerland, 6‐9 November 2019   06 novembre 2019
HIV-infected patients aged above 75years.
Medecine et maladies infectieuses   11 mai 2019
Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
Journal of hepatology   06 avril 2019
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
Hepatology (Baltimore, Md.)   04 mars 2019
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Medecine et maladies infectieuses   21 décembre 2018
Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.
Transplantation   18 septembre 2018